Bibliographic Production

1. Stockdale AJ, Phillips RO, BeloukasAAppiah LY, Chadwick D,Bhagani S,Bonnett L, Sarfo FS,Dusheiko G, Geretti AM.  HEPIK Study Group.Liver fibrosis and virological outcomes after introduction of tenofovir in extensively lamivudine-experienced adults with HIV and hepatitis B virus (HBV) co-infection in Ghana. Clin Infec Dis (in press).
2. Baxter JD, Dunn D, White E, Sharma S, Geretti AM, Kozal MJ, Johnson MA, Jacoby S, Llibre JM, Lundgren J. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. HIV Med 2015;16Suppl 1:77-87.
3. Geretti AM, Paredes R, Kozal MJ.Transmission of HIV drug resistance: lessons from sensitive screening assays.CurrOpin Infect Dis 2015;28:23-30.
4. King S, Adjei-Asante K, Appiah L, Adinku D, Beloukas A, Atkins M, Sarfo SF, Chadwick D, Phillips RO, Geretti AM.Antibody screening tests variably overestimate the prevalence of hepatitis C virus infection among HIV-infected adults in Ghana. J Viral Hepat 2015;22:461-8.
5. Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'ArminioMonforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ; on behalf of the CHAIN Minority HIV-1 Variants Working Group. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J AntimicrobChemother 2015;70:930-40.
6. Geretti AM, Tsakiroglou M.HIV: new drugs, new guidelines.CurrOpin Infect Dis 2014;27:545-53.
7. Aoudjane S, Chaponda M, González Del Castillo AA, O'Connor J, Noguera M, Beloukas A, Hopkins M, Khoo S, van Oosterhout JJ, Geretti AM.Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi. Clin Infect Dis 2014;59:1618-26.
8. Sarfo FS, Kasim A, Phillips R, Geretti AM, Chadwick DR. Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana. J Infect. 2014;69:481-9.
9. Matthews PC, Geretti AM, Goulder PJ, Klenerman P.Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol. 2014;61:20-33.
10. Gökengin D, Geretti AM, Begovac J, Palfreeman A, Stevanovic M, Tarasenko O, Radcliffe K.2014 European Guideline on HIV testing.Int J STD AIDS.2014;25:695-704.
11. Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G, Brown A, Castelino S, Cooke G, Fisher M, Geretti AM, James R, Kulasegaram R, Leen C, Mutimer D, Orkin C, Page E, Palfreeman A, Papineni P, Rodger A, Tong CY; British HIV Association.British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med. 2013;14Suppl 4:1-71.
12. Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, Seguin-Devaux C, Verhofstede C, Wirden M, Amendola A, Boni J, Bourlet T, Huder JB, Karasi JC, ZidovecLepej S, Lunar MM, Mukabayire O, Schuurman R, Tomazic J, Van Laethem K, Vandekerckhove L, Wensing AM; International Viral Load Assay Collaboration.Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J Clin Microbiol 2014;52:517-23.
13. Foster GM, Ambrose JC, Hué S, Delpech VC, Fearnhill E, Abecasis AB, Leigh Brown AJ, Geretti AM; UK HIV Drug Resistance Database. Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D. PLoS One 2014;9:e83337.
14. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). HIV Med 2014 ;15Suppl 1:1-85.
15. Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y; SENSE Study Group.Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. J AntimicrobChemother 2014;69:1090-7.

Other relevant publications

1. Geretti AM, Doyle T.Immunization for HIV-positive individuals.CurrOpin Infect Dis 2010;23:32-8.
2. Molton J, Smith C, Chaytor S, Maple P, Brown K, Johnson M, Geretti AM. Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. J Infect. 2010;61:73-80.
3. Geretti AM, BHIVA Immunization Writing Committee, Brook G, Cameron C, Chadwick D, Heyderman RS, MacMahon E, Pozniak A, Ramsay M, Schuhwerk M.British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008;9:795-848.
4. Chadwick DR, Geretti AM.Immunization of the HIV infected traveller. AIDS 2007;21:787-94.